The Broad Institute of MIT and Harvard
Cambridge, United States
Dr. Dana Silverbush is a postdoctoral researcher in the pathology department at Massachusetts General Hospital and The Broad Institute of MIT and Harvard. With a strong interdisciplinary focus, she works closely with clinicians and collaborators to design cutting-edge analytical tools that address the most essential unresolved questions in cancer research. Using data from genetic, epigenetic, and transcriptomic sources (collectively known as multiple omics), her research focuses on building algorithmic solutions to study the multi-dimensional processes leading to cancer heterogeneity and plasticity. Understanding these processes is essential for ensuring accurate diagnosis and effective prognostication in cancer patients.
Dana received her PhD in Computer Science (with a focus on Computational Biology) from Tel-Aviv University, where she built algorithmic solutions to decipher abnormal signaling pathways and multi-omic programs involved in cancer progression. To bridge the gap between algorithm design and practical clinical needs, she joined the labs of Dr. Mario Suva (Massachusetts General Hospital) and Dr. Aviv Regev (The Broad Institute of Harvard and MIT). Her postdoctoral work has focused on analyzing the genetic and epigenetic factors that drive intra-tumoral heterogeneity in glioma and contribute to tumor plasticity.
Dana received an NCI K99/R00 Pathway to Independence Award in 2020 and is currently completing the K99 phase. She has previously received funding for her research from the National Institutes of Health, the European Molecular Biology Organization, and the Schmidt Family Foundation.